# Safety of Flonoltinib Maleate Tablets for the Treatment of Patients With Myeloproliferative

> **NCT05153343** · PHASE1,PHASE2 · COMPLETED · sponsor: **Chengdu Zenitar Biomedical Technology Co., Ltd** · enrollment: 31 (actual)

## Conditions studied

- Myeloproliferative Neoplasm (MPN)
- Myelofibrosis，MF

## Interventions

- **DRUG:** flonoltinib 25mg
- **DRUG:** flonoltinib 100mg
- **DRUG:** flonoltinib 150mg
- **DRUG:** flonoltinib 225mg
- **DRUG:** flonoltinib 50mg

## Key facts

- **NCT ID:** NCT05153343
- **Lead sponsor:** Chengdu Zenitar Biomedical Technology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-27
- **Primary completion:** 2023-11-29
- **Final completion:** 2025-03-19
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2025-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05153343

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05153343, "Safety of Flonoltinib Maleate Tablets for the Treatment of Patients With Myeloproliferative". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT05153343. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*